unit state go sg websit
stock offer everyth
upsid tp
think abbv therapeut exposur make larg cap pharma
stock least like hit price pressur us addit
expect market-lead posit immuno-inflamm blood
cancer deliv best-in-class growth cash return
sharehold although comfort best-perform
larg cap pharma stock last month valuat still
undemand linger misconcept over-reli
humira view expect rerat driven investor
grow convict abil increasingli credibl manag
team diversifi stock market fulli discount long rang
 risk-adjust non-humira revenu tp would potenti
rise
chang upgrad non-gaap ep estim
higher sale mavyret hepat humira anti-inflamm us tax reform
new buy-back announc late last week off-set lower profit new ep
estim ahead consensu still expect base busi
late-stag pipelin surpris posit
valuat alway tp base straight averag ev/ebita
multipl dcf increas tp
reflect upgrad estim also assign higher
premium sector ev/ebita vs previous follow recent
halv abbv tax rate make even attract rel sector new
tp impli price-to-earnings premium global pharma coverag univers
sector continu expect deliv high-qual sale ep
growth rate consist well sector averag dividend
estim tp impli tsr
nc chang
risk tp rate recommend would downsid
group ebit forecast humira annual us eros post biosimilar entri year
mid-teen rather high-singl digit magnitud downsid would
similar either risankizumab jak inhibitor fail commercialis
pipelin fail might cut dividend help fund major acquisit
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
america corp
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet feb cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
straight averag sotp base averag ev/ebita multipl dcf wacc termin growth
would downsid group ebit forecast humira annual us eros post biosimilar entri year mid-
teen rather high-singl digit magnitud downsid would similar either risankizumab jak inhibitor
fail commercialis pipelin fail might cut dividend help fund major acquisit
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act co-manag novarti financ bond
